HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LTRN
Lantern Pharma Inc.
There isn't enough reported data to score LTRN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LTRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LTRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LTRN PE Valuation
LTRN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LTRN Forward outlook
There aren't enough analyst estimates for LTRN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.62 | +$0.16 |
| Q1 2026 | -$1.45 | +$0.39 |
| Q4 2025 | -$1.57 | +$0.36 |
| Q3 2025 | -$1.75 | +$0.02 |
| Q2 2025 | -$1.78 | -$0.14 |
| Q1 2025 | -$1.84 | -$0.22 |
| Q4 2024 | -$1.93 | -$0.46 |
| Q3 2024 | -$1.77 | -$0.37 |
LTRN is still losing money, but less than at its worst: $1.62 per share over the past year, against $1.93 at its worst in late 2024.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LTRN Quarterly Revenue
LTRN and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
LTRN has the stronger cash trend. Its trailing FCF is down 21% versus its history, compared with HIMS at down 84%.
LTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$2.8M | +$1.2M |
| Q3 2025 | -$4.6M | +$1M |
| Q2 2025 | -$3.9M | +$1.3M |
| Q1 2025 | -$4.4M | -$1.3M |
| Q4 2024 | -$4M | -$584.4K |
| Q3 2024 | -$5.6M | -$2M |
| Q2 2024 | -$5.2M | -$1.6M |
| Q1 2024 | -$3.1M | +$695.3K |
LTRN has burned cash in almost every quarter: −$16M over the past year, against −$18M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LTRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LTRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +1.2M shares |
| 1 year | +15% | +1.6M shares |
| 3 years | +14% | +1.6M shares |
| 5 years | +11% | +1.2M shares |
| Available history | +100% | +6.2M shares |
LTRN has 12M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LTRN Net Leverage
LTRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.8 | Oversold |
| Stochastic | 2.1 | Oversold |
LTRN's weekly RSI is 24 (oversold) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LTRN PE vs Healthcare Sector
LTRN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.74 | 38% below |
| 20 week MA | $1.84 | 75% below |
| 50 week MA | $2.49 | 82% below |
| 100 week MA | $3.18 | 86% below |
| 200 week MA | $3.94 | 88% below |
LTRN is in a downtrend: it's below all five of its weekly moving averages, and 88% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over LTRN on returns for 2026, with the stronger performance.
LTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $19.2 | +30% |
| 2021 | $19.2 | $7.31 | -62% |
| 2022 | $7.31 | $5.62 | -23% |
| 2023 | $5.62 | $4.28 | -24% |
| 2024 | $4.28 | $3.42 | -20% |
| 2025 | $3.42 | $3.48 | +1.8% |
| 2026 YTD | $3.48 | $0.46 | -87% |
LTRN has finished lower in four of the last six years. It's down 87% so far in 2026.